title: [Novel controllers of airway obstruction in COPD patients].
abstract: For improving effectiveness of chronic obstructive pulmonary disease (COPD) therapy is necessary to influence on pharmacologic receptors in the complementary way and to reduce the dose frequency. The once-daily dose administration is an important step which may allow to enhance of patients compliance. Novel long-acting bronchodilators--beta2-agonists or ultra long-acting beta2-agonists (LABAs) such as indacaterol and carmoterol--are under clinical application for the treatment of COPD patients. Moreover, some new long-acting antimuscarinic agents (LAMA) (aclidinium, glycopyrrolate) and dual-action ultra LABA+LAMA combination products are under development. The main target of therapeutic research is to produce a dimmer molecule known as M3 antagonist-beta2 agonist (MABA) bronchodilators which will open the door for a new range of combination products.
authors.affiliation: Wojskowy Instytut Medyczny w Warszawie, Klinika Chorób Wewnetrznych, Pneumonologii i Alergologii CSK MON.
authors.forename: Tadeusz
authors.initials: T
authors.lastname: Płusa
mesh_terms: D000402:Airway Obstruction / Q000188:drug therapy*; D000662:Amphetamines / Q000008:administration & dosage; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006801:Humans; D006912:Hydroxyquinolines / Q000008:administration & dosage; D007189:Indans / Q000008:administration & dosage; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D010349:Patient Compliance; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000503:physiopathology; D015363:Quinolones / Q000008:administration & dosage
chemical_list: D000662:Amphetamines; D001993:Bronchodilator Agents; D004338:Drug Combinations; D006912:Hydroxyquinolines; D007189:Indans; D018727:Muscarinic Antagonists; D015363:Quinolones; C510790:indacaterol; C074413:carmoterol